Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
MOSES
Evaluation of the Role of Tongue Base MucOsectomy and Step sErial Sectioning in the Management of the Unknown Primary Squamous Cell Cancer in the Head and Neck
1 other identifier
observational
100
1 country
1
Brief Summary
Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck. Clinical examination and imaging investigations are performed to try and identify the site where the cancer has originated. However, if no original site can be identified, then the investigators call these 'cancers of an unknown primary' (CUP) of the head and neck. One region where these cancers could have originated from is the oropharynx. There are two areas in the oropharynx were cancers commonly arise. One area is the palatine tonsils, which can be removed for analysis with an operation called tonsillectomy. The other area is the tissue lining the back of the tongue, known as the tongue base. A relatively new surgical technique called 'tongue base mucosectomy' (TBM) allows removal of this tissue to see if the primary cancer is contained within it. This study will then use a histological method called 'step serial sectioning' (SSS) to look in more detail at the tonsils and tongue base, hoping to increase the detection rate of the primary cancer. Centres performing TBM will be asked to participate. Patients will be asked to consent to their tissue being used for SSS after it has undergone conventional histology. Anonymised samples will be sent to a central laboratory in Newcastle for processing. Other anonymised data regarding the patients' diagnosis and care will be collated. Patients will be asked to complete questionnaires regarding pain and swallowing recovery following surgery. A smaller cohort of patients will also be interviewed as part of a qualitative research process to establish their views on CUP and the acceptability of the above treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 10, 2019
CompletedStudy Start
First participant enrolled
November 1, 2019
CompletedFirst Posted
Study publicly available on registry
November 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
February 12, 2026
February 1, 2026
10.1 years
October 10, 2019
February 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Primary Cancers Identified
Cancer identified in tonsil and tongue base resections
Within one year of surgery
Secondary Outcomes (2)
Pain after tongue base mucosectomy
week 0 , 3 weeks, 6 weeks, 12 weeks, 26 weeks and 52 weeks
Swallow function after tongue base mucosectomy
week 0 , 3 weeks, 6 weeks, 12 weeks, 26 weeks and 52 weeks
Interventions
Step serial sectioning histological processing
Eligibility Criteria
Cervical metastatic SCC, confirmed with cytology or biopsy, undergoing TBM for identification of primary site
You may qualify if:
- Aged 16 or over
- Both sexes
- Cervical metastatic SCC, confirmed with cytology or biopsy, undergoing TBM for identification of primary site
You may not qualify if:
- Primary site identified by any means prior to being indicated for TBM
- Patients undergoing targeted biopsies or resections
- Patients known to have a history of previous H\&N cancers
- Patients known to have undergone previous radiation to the H\&N region
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institute of Cancer Research, United Kingdomcollaborator
- Oracle Cancer Trustcollaborator
- Royal Marsden NHS Foundation Trustlead
Study Sites (1)
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Biospecimen
Tonsil and tongue base resection specimens,buccal swab and/or blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 10, 2019
First Posted
November 5, 2019
Study Start
November 1, 2019
Primary Completion (Estimated)
December 1, 2029
Study Completion (Estimated)
December 1, 2030
Last Updated
February 12, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share